Dabrafenib 200 mg | Purity Not Available
TargetMol
Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase (IC50s: 0.7/5 nM for B-Raf (V600E)/C-Raf).
More Information Supplier PageDabrafenib
Search Results
Bikinin 200 mg | 99.91%
TargetMol
Bikinin, a potent inhibitor of plant GSK-3/Shaggy-like kinase, activates BR signaling downstream of the BR receptor.
More Information Supplier PageBikinin
CTX-0294885 2 mg | 99.95%
TargetMol
CTX-0294885, a novel bisanilino pyrimidine, exhibits inhibitory activity against a broad range of kinases in vitro and is further developed into a Sepharose-supported kinase capture reagent.
More Information Supplier PageCTX-0294885
Navitoclax 100 mg | 98.88%
TargetMol
Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family protein inhibitor that avidly binds Bcl-2, Bcl-xL, and Bcl-W (Ki < 1 nM for all three proteins).
More Information Supplier PageNavitoclax
ABT-737 100 mg | 99.30%
TargetMol
ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w (EC50s: 78.7/30.3/197.8 nM).
More Information Supplier PageABT-737
APD668 2 mg | 99.97%
TargetMol
APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119, respectively.
More Information Supplier PageAPD668
APD668 1 mg | 99.97%
TargetMol
APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119, respectively.
More Information Supplier PageAPD668
Raf inhibitor 1 25 mg | 98.05%
TargetMol
Raf inhibitor 1
Raf inhibitor 1 2 mg | 98.05%
TargetMol
Raf inhibitor 1
Mutant IDH1-IN-1 1 mg | 98.98%
TargetMol
Mutant IDH1-IN-1 is a potent mutant IDH1 R132 h inhibitor with IC50 < 0.1 uM.
More Information Supplier PageMutant IDH1-IN-1
